David Herrington to Heptanoic Acids
This is a "connection" page, showing publications David Herrington has written about Heptanoic Acids.
Connection Strength
0.337
-
Chotenimitkhun R, D'Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, Lash TL, Yeboah J, Herrington DM, Hundley WG. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015 Mar; 31(3):302-7.
Score: 0.121
-
Puntawangkoon C, Morgan TM, Herrington DM, Hamilton CA, Hundley WG. Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin. Menopause. 2010 Jan-Feb; 17(1):114-20.
Score: 0.086
-
Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007 Jul 03; 147(1):1-9.
Score: 0.073
-
Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004 Jan 15; 93(2):154-8.
Score: 0.057